SOUTH SAN FRANCISCO, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of the Hyperion™ Imaging System, significantly expanding the number of protein markers that researchers can simultaneously detect in tumors and tissues.
Providing unprecedented visualization of complex cellular phenotypes and their relationships in the context of cancer, immuno-oncology, and immune-mediated diseases, the system has the potential to revolutionize disease research and empower the development of better diagnostics and more effective therapies in the future.
Developed using proven Fluidigm® CyTOF® technology, the Hyperion Imaging System surpasses the inherent limitations of fluorescence detection by using highly pure metal tags that are separated by mass instead of by wavelength. Setting a new standard in highly multiplexed protein detection, the system enables researchers to simultaneously image 4 to 37 protein markers with minimal background. With the ability to utilize up to 135 channels to detect additional parameters, the Hyperion Imaging System can meet the needs of researchers well into the future.
Ideal for deep profiling of precious formalin-fixed, paraffin-embedded (FFPE) and fresh frozen tissue samples, the Hyperion Imaging System maximizes the results that can be obtained from each sample by Imaging Mass Cytometry™ and eliminates the variability that comes from the use of serial sections or sequential staining. Further, by preserving the information that is available in tissue architecture and cellular morphology, researchers can gain new insights in the context of the tissue microenvironment, all at subcellular resolution.
“By looking at 35 different antigens in a tissue section and their relationship to each other, we can really get new insights about cell heterogeneity—cell interactions—that we weren’t able to even approach before,” said Klaus Kaestner, PhD, MS, Thomas and Evelyn Suor Butterworth Professor in Genetics at the University of Pennsylvania Perelman School of Medicine.
Offered as a complete workflow solution, the Hyperion Imaging System is accompanied by a pathologist-verified Maxpar® imaging antibody portfolio, labeling kits, a software suite for image acquisition and data analysis and experienced Fluidigm service and support. Concurrent development of this comprehensive offering ensures that researchers have access to research and analytical tools and training critical to success.
“With over 30 systems enabled globally, progress in applying this innovative technology to ask new questions across a number of disease research areas is truly impressive,” said Chris Linthwaite, President and CEO of Fluidigm. “During a recent meeting with our early adopters of this system in Zurich, Switzerland, researchers from academia and pharma shared best practices and insights gained from applying this transformative technology in their own research programs.”
“Because we are interested in the tumor ecosystem, an approach like Imaging Mass Cytometry is an absolute necessity to reveal the level of information that includes cell type identity, the functional state of individual cells and the spatial relationships of those cells,” said Bernd Bodenmiller, PhD, Assistant Professor at the University of Zurich and a key innovator in the field of Imaging Mass Cytometry.
“Imaging Mass Cytometry has a lot of potential in discovery of biomarkers, and we’re very excited about its potential to multiplex,” said David Rimm, MD, PhD, Professor of Pathology at Yale University School of Medicine. “The importance of doing more than one at a time is not only the fact that you’re measuring more than one at a time, but the relationship to each other. I see Imaging Mass Cytometry as a discovery tool that can provide information about which molecules are most important to predict response to therapy.”
“We are excited to announce the commercialization of the Hyperion Imaging System and bring the benefits of Imaging Mass Cytometry to the larger translational research community,” said Linthwaite. “In our announcement event today, we will share more information about this new revolutionary application together with leading researchers.”
The announcement event at 10 a.m. ET will be livestreamed at fluidigm.com/futureofimaging.
“As a growing community, we look forward to the new insights that will come from the application of Imaging Mass Cytometry across a range of diseases to improve the future of health care,” Linthwaite said.
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single‑cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm, the Fluidigm logo, CyTOF, Maxpar, Hyperion, and Imaging Mass Cytometry are trademarks or registered trademarks of Fluidigm Corporation.
Forward-Looking Statement for Fluidigm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the benefits and uses of the Hyperion Imaging System. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to uncertainties in contractual relationships and international regulated markets; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; the uncertain regulatory environment; potential product performance and quality issues; intellectual property risks; competition; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; and risks associated with international operations. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results are contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2016, and in its other filings with the Securities and Exchange Commission, including Fluidigm’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Senior Director, Marketing
650 737 4190